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Abstract Anandamide (arachidonylethanolamide) is a novel 
lipid neurotransmitter first isolated from porcine brain which has 
been shown to be a functional agonist for the cannabinoid CB1 
and CB2 receptors. Anandamide has never been isolated from 
human brain or peripheral tissues and its role in human 
physiology has not been examined. Anandamide was measured 
by LC/MS/MS and was found in human and rat hippocampus 
(and human parahippocampal cortex), striatum, and cerebellum, 
brain areas known to express high levels of CB1 cannabinoid 
receptors. Significant levels of anandamide were also found in the 
thalamus which expresses low levels of CB1 receptors. Ananda- 
mide was also found in human and rat spleen which expresses 
high levels of the CB2 cannabinoid receptor. Small amounts of 
anandamide were also detected in human heart and rat skin. 
Only trace quantities were detected in pooled human serum, 
plasma, and CSF. The distribution of anandamide in human 
brain and spleen supports its potential role as an endogenous 
agonist in central and peripheral tissues. The low levels found in 
serum, plasma, and CSF suggest hat it is metabolized in tissues 
where it is synthesized, and that its action is probably not 
hormonal in nature. 
Key words: Anandamide; Cannabis; Cannabinoid receptor; 
Marijuana 
porcine brain and found to be a lipid of novel structure [7]. 
Anandamide displayed specific binding to the CBI receptor 
and inhibited a prototypical twitch response in mouse vas 
deferens. Anandamide has also been shown to induce similar 
behavioral [8,9], pharmacological [10,11], and signal transduc- 
tion effects [12] as classical cannabinoid agonists, but high 
concentrations were required to induce these effects. Levels 
of anandamide were first estimated to occur at 0.4 pmol/g 
(133 pg/g) in whole porcine brain [7], and recently quantitated 
in porcine and bovine brain at 173 pmol/g (60 ng/g) and 101 
pmol/g (35 ng/g) respectively [13]. A recent study reports levels 
of anandamide in rat testis to be considerably lower (6 pmol/ 
g, 2.1 ng/g) [14]. However, anandamide has never been iso- 
lated from human tissue or fluids. Furthermore, levels of an- 
andamide have not been measured in regions of rat brain or 
in tissues such as spleen where CB2 receptors have been 
shown to be expressed at high levels. Studies of anandamide 
distribution should help elucidate the physiologic role of an- 
andamide as a cannabimimetic eicosanoid and possibly broad- 
er functions. In this study we report the isolation and quanti- 
tation of anandamide by liquid chromatography/mass 
spectrometry in various tissues and fluids from postmortem 
human and rat. 
1. Introduction 
The psychotropic and therapeutic effects of cannabinoids, a 
class of compounds derived from the marijuana plant, have 
been known for centuries, but only relatively recently has the 
mechanism of their actions been elucidated. To date, three 
receptor subtypes have been identified which bind cannabi- 
noids and related compounds with high affinity. The CBI 
receptor [1] and splice variant, CBIa  [2], are found predomi- 
nantly in the central nervous system. The CB2 receptor is 
found predominantly in spleen and hemopoietic ells and 
has a 44% overall nucleotide sequence identity with the CB1 
receptor [3-5]. In spite of these dissimilarities in structure and 
distribution, the CB1 and CB2 receptors bind most cannabi- 
noid agonists with similar affinity [6]. The discovery of canna- 
binoid receptors uggested that an endogenous ligand may be 
found in areas of receptor expression. 
The first endogenous cannabimimetic compound, ananda- 
mide (arachidonylethanolamide), was isolated from whole 
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2. Materials and methods 
Anandamide (arachidonylethanolamide) and (5,6,8,9,11,12,14,15- 
Ds)anandamide were obtained from Biomol (Plymouth Meeting, 
PA). TLC plates (60 ,~, 250 /am silica gel K6, 20 x 20 cm) were ob- 
tained from Whatman (Clifton, N J). All other reagents were obtained 
from Sigma. 
2.1. Isolation and extraction of rat and human tissues or fluids 
Normal human brain samples from individuals uffering acute car- 
diac failure (age 48 and 62) were obtained within 2 h post mortem and 
processed for routine histopathology and regions frozen at -70°C 
until use. Human serum, plasma, and cerebral spinal fluid were the 
generous gift from Dr. Robin Felder (Department of Pathology, Uni- 
versity of Virginia, Charlottesville, VA) and were frozen at -70°C 
within 2 h of collection. Human serum, plasma, and cerebral spinal 
fluid were randomly pooled from at least 10 patients per sample. 
Female Sprague-Dawley rats were obtained from Taconic Farms 
(Germantown, NY) and anesthetized by brief CO2 asphyxiation, de- 
capitated, and tissues removed by surgical dissection within 5 min. All 
samples were snap frozen in liquid N2 and stored at -70°C until use. 
All tissues and fluids were homogenized in buffer (200 mM sucrose, 50 
mM Tris-HC1, 5 mM MgCI2, 2.5 mM EDTA, pH 7.4) containing 66% 
toluene (v/v) and then extracted at room temperature three times with 
2 volumes, 2 volumes, and 1 volume toluene, respectively. Toluene 
extracts were pooled and dried under N2 gas to a final volume of 
approximately 1 ml and streaked on TLC plates which were then 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
Pl l  SO0 1 4 -5793(96)0089 1 -5 
232 (Z C Felder et al./FEBS Letters 393 (1996) 231~35 
A lOO 370.5 B lOO 62.2 
C 
"E 
E 
348.5 
75 
50' 
25 ¸ 
c , L ,a . . , . -  . , ,  ~ ~ 4 , - J L . .  . . . . .  ~ . . . ,  . . . .  , . ,  h . ,~. . .~ . . . . . . .  . . . . . .  
~00 ~so ~00 350 ,00 ,50 500 
m/z 
348.3/62.1 4740 
100" 
50"75"_ . . . . . . .  
25- 
0~ ; . . . . . . . .  . • 
356,3/62.1 1215 
100" 
75- 
50" 
25" 
0.0 2'.5 5.0 7.5 10.0 12.5 
Time (min) 
100 200 300 400 
m/z 
D 348.3/62.1 657 
'E 
100- 
75- 
50- 
25- 
0 
356.3/62.1 
100- 
75- 
50- 
25- 
0~ 
0.0 
E 
85 
2.5 5.0 
Time (min) 
7.5 10.0 12.5 
2 '  
0 ~ , , , 
0.0 
y = 7.6833e-2 + 1.9961x R^2 = 0.996 
• i . . . .  i . . . .  
0.5 1.0 1.5 
ANM/d8  (mo lar )  
Fig. 1. A: ESI-MS spectrum of anandamide between m/z=200 and m/z= 500. A solution of anandamide (0.1 mg/ml in methanol) was infused 
into the mass spectrometer. The ion at m/z = 348.5 represents the protonated molecular ion, (M+H) + (molecular weight of anandamide = 347.3) 
and the ion at m/z= 370.5 represents the sodium adduct of that ion (M+H+Na) +. B: Product ion spectrum of m/z = 348.4 ion. A solution of 
anandamide (6.9 mg/ml in methanol) was infused into the mass spectrometer. The ion at m/z = 348.4 was selected as the precursor ion for MS/ 
MS analysis and the resulting product ion spectrum was recorded between m/z = 40 and m/z = 500. C: LC/MS/MS chromatogram of a mixture 
of anandamide and deuterated anandamide standards. A solution containing anandamide (2.0 gM) and deuterated anandamide (1.6 taM) was 
injected onto the reversed-phase column and the column effluent was monitored in MRM mode as described in Section 2. The upper trace rep- 
resents the anandamide response and the lower trace represents tile deuterated anandamide response. D: LC/MS/MS chromatogram of a sam- 
ple of an extract of rat striatum with deuterated anandamide added as an internal standard. Details of the chromatography and column moni- 
toring are given in Section 2. The upper trace represents the anandamide response and the lower trace represents the deuterated anandamide 
response. E: Anandamide standard curve. Four standard mixtures containing anandamide and deuterated anandamide were prepared, each 
with a constant concentration of deuterated anandamide (1.6 ~tM) and increasing concentrations of anandamide (0, 0.4, 1.0, and 2.0 gM). Each 
was analyzed by the LC/MS/MS procedure described in Section 2. The data are displayed as the area ratio of anandamide to deuterated an- 
andamide as a function of the molar ratio of anandamide to deutcrated anandamide. 
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developed in the following organic solvent mixture (40:20:5, v/v/v, 
chloroform:hexane:methanol). The area of the TLC plate that mi- 
grated with an authentic anandamide standard was scraped and eluted 
with chloroform:methanol (85:15, v/v), dried under N2, and resus- 
pended in 50 /al methanol and stored at -70°C. 50 ng of ananda- 
mide-D8 was added to all samples before the extraction procedure and 
final data normalized to anandamide-Ds content. Recovery of 
[3H]anandamide following these extraction procedures was greater 
than 80%. 
2.2. Liquid chromatography/mass spectrometry 
An LC/MS/MS assay was utilized to quantify the amount of an- 
andamide semi-purified from tissues and fluids because of its selectiv- 
ity and sensitivity. The sample was injected, in a volume of 5 ~tl 
MeOH, onto a C-18 reversed-phase HPLC column (Hypersil C18, 
1.0 mmx 20 mm, Keystone Scientific, equilibrated in 20% methanol) 
flowing at 50/al/min. The solvent composition was ramped from 20% 
to 99% methanol in 1 min and then held constant at 99% methanol 
for 14 rain to elute the analyte from the column. The column effluent 
was directed through a fused silica capillary (50/am in diameter) into 
the source of an electrospray ionization triple quadrapole mass spec- 
trometer (API-III, PE SCIEX, Concord, Ontario). Mass spectrometer 
operating parameters were optimized before each set of samples was 
analyzed and were set to approximately the following values: orifice 
potential =+65 V; collision gas thickness =250 x 1012 molecules/cm 2. 
The instrument was operated in MRM (multiple reaction monitoring) 
mode whereby only two ions, m/z = 348.3 and m/z = 356.3, correspond- 
ing to the singly charged protonated molecular ions of anandamide 
and the deuterated form of anandamide, respectively, were allowed to 
pass into the collision chamber and were monitored simultaneously. A 
representative spectrum of anandamide standard is shown in Fig. 1A. 
Both forms of anandanaide fragment to give a prominent product ion 
of m/z = 62.1 (Fig. 1B). Detection of anandamide, therefore, is based 
on the fragmentation of the precursor ion of m/z = 348.3 to yield a 
prominent product ion m/z = 62.1. The deuterated form of anandamide 
serves as an internal standard and its detection is based on the frag- 
mentation of the precursor ion of m/z = 356.3 to yield m/z-- 62.1. An 
example of a chromatogram showing the separation and detection of 
both anandamide and deuterated anandamide in a standard mixture 
and in rat striatum is shown in Fig. IC,D. A standard curve (Fig. 1E) 
obtained by injecting mixtures of anandamide and deuterated ananda- 
mide in different ratios with constant deuterated anandamide shows a 
good linear relationship between the ratio of integrated peak areas 
and the ratio of molar amounts of the two components. The lower 
limit of detection by this assay was estimated to be approximately 150 
nM in the injected sample. 
3. Results and discussion 
Lipids from human and rat tissues or fluids were organic 
solvent extracted, semi-purified by thin layer chromatography,  
and analyzed for anandamide content by LC/MS/MS. The 
results of this study are the first report of anandamide in 
regions of human and rat brain (Fig. 2A,B). Relatively similar 
levels of anandamide were found in the four regions of rat 
brain studied (Fig. 2A). The highest level was found in the 
h ippocampus (29 pmol/g) and the lowest level was found in 
the thalamus (20 pmol/g). The levels of anandamide in rat did 
not vary more than 10 pmol/g over the four brain regions 
evaluated. In contrast, considerable differences were seen in 
human brain distr ibution and may reflect regional differences 
in tissue samples selected. The five human brain regions se- 
lected for analysis ranged from 25 pmol/g in cerebellum to 148 
pmol/g in h ippocampus (Fig. 2B). Also reported in this study 
is the presence of anandamide in human and rat spleen sug- 
gesting that it may also play a role as an endogenous agonist 
in this organ (Figs. 2 and 3). Anandamide was also found in 
rat skin at levels comparable to those in rat brain. 
The absence of anandamide in human serum, plasma, and 
CSF (Fig. 2B) suggests that anandamide is not hormonal  in 
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Fig. 2. A, B: Distribution of anandamide in selected regions of rat 
and human. Samples were homogenized and extracted in toluene in 
the presence of internal anandamide-Ds standard, purified by TLC, 
and analyzed by LC/MS/MS as described in Section 2. Data from 
human samples are the mean + SEM from at least two individuals 
and each sample was measured at least twice (except for hippocam- 
pus and parahippocampal cortex in which small tissue samples al- 
lowed only single determinations for each patient and therefore the 
data are the mean + standard eviation). Rat tissue was pooled from 
six male rats and replicate measurements performed (data are the 
mean + SEM). Anandamide was extracted from two pools of human 
serum, plasma, and CSF collected and combined from at least 10 
patients in each pool. Total fluid volumes for both pools are as fol- 
lows: serum (132 ml and 72 ml), plasma (36 ml and 41 ml), CSF 
(115 ml and 59 ml). Two replicate measurements were performed 
for each pool of plasma and CSF and one determination was per- 
formed for each pool of serum. 
nature, requiring that it be synthesized in an endocrine organ 
and released to the circulation to act on distant tissues. How- 
ever, pressor and depressor effects of anandamide on heart 
rate and blood pressure have been recently described [15]. 
The depressor effects were thought o be sympatho-inhibitory, 
augmenting noradrenal ine release from sympathetic ganglion 
through CB1 receptors localized on the terminals of post- 
ganglionic sympathetic neurons (Lake et al., 1996, ICRS). 
However, in this study an additional pressor effect on periph- 
eral vasculature could not be explained by this mechanism 
and a direct, non-CB1 receptor-mediated ffect of anandamide 
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Fig. 3. Postmortem levels of anandamide in human cerebellum. A 
human brain was obtained less than 1 h post mortem and adjacent 
samples collected from cerebellar cortex at the times indicated. The 
tissue remained at room temperature during the entire collection 
period. Data are the mean + standard eviation of duplicate determi- 
nations and are representative of two experiments. 
on smooth muscle was proposed. We find small amounts of 
anandamide in human heart where a low level of CB1 mRNA 
has also been measured [5]. It is not clear if heart muscle 
synthesizes anandamide or if trace quantities of circulating 
anandamide accumulate in areas of CB1 receptor expression. 
It is possible that anandamide is synthesized and partly me- 
tabolized in circulating hemopoietic ells. In contrast, testis 
has been shown to contain significant levels of CB1 receptors 
[5], as well as anandamide and an anandamide containing N- 
acylphospholipids [14] suggesting that anandamide is gener- 
ated near the location of the CB1 receptor in this tissue. 
Recent evidence suggests that anandamide levels may in- 
crease significantly as postmortem collection time increases 
beyond 5 h in porcine and bovine brain [13]. We observed 
similar results in human cerebellum measured over a 24 h 
period (Fig. 3). However, all human samples in this study 
were collected within 2 h and rat samples within 5 min post 
mortem suggesting that postmortem delay would have little 
influence on anandamide l vels in these studies. The increase 
in anandamide l vels over postmortem time may result from 
activation of one or both currently proposed synthetic routes 
for anandamide formation. The most widely accepted biosyn- 
thetic pathway suggests that anandamide formation results 
from the degradation of a putative storage form of ananda- 
mide, N-arachidonylphosphatidylethanolamine, through acti- 
vation of a sn-3 position phosphohydrolase uch as phospho- 
lipase D [13,14,16]. Alternatively, a putative anandamide 
synthase nzyme would condense arachidonic acid and etha- 
nolamine following their release from phospholipids by phos- 
pholipases A2 and D respectively [17,18]. It is not clear which 
of these two pathways or possible alternative pathways pre- 
dominate during postmortem release of anandamide. Post- 
mortem levels of anandamide may be determined by the equi- 
librium between the proposed routes of formation and its 
degradation by a partially characterized aminohydrolase 
[19]. More detailed study of the regulation of anandamide 
synthesis hould help answer these questions. 
The measurement of anandamide in human tissues expres- 
sing cannabinoid receptors upports the hypothesis that an- 
andamide is an authentic endogenous agonist for this family 
of receptors. Previous reports have shown similarities in the 
behavioral responses resulting from cannabinoid agonists and 
anandamide in various well studied animal models [8,10]. 
Anandamide displays pharmacological nd biochemical prop- 
erties of a cannabinoid agonist for both the CB1 and CB2 
receptors [6]. Furthermore, cannabinoid receptors how speci- 
ficity for polyunsaturated fatty acylethanolamides with struc- 
tural similarities to anandamide [12]. However, measurement 
of anandamide at significant levels in tissues uch as heart and 
thalamus known to express few if any cannabinoid receptors 
and its relatively low affinity for both CB1 and CB2 receptors 
suggest hat other receptors may exist for anandamide [20]. In 
addition, cannabinoid receptor-independent effects of ananda- 
mide have been reported [21], suggesting the presence of other 
anandamide binding sites. 
The wide distribution of anandamide in brain and in per- 
ipheral tissues suggests that anandamide represents a new 
class of lipid neurotransmitter with little resemblance to 
well-studied biogenic amines, amino acids, or peptides. Its 
lipid character and ability to permeate membranes uggest 
that vesicular storage is unlikely, and that storage would 
more likely occur in the lipid bilayer as components of phos- 
pholipids. The levels of anandamide measured in human brain 
are not unlike those previously reported for dopamine and 
serotonin [22], but at least 10-fold lower than those reported 
for GABA and glutamate [23]. However, our measurements of 
anandamide most likely represent a combination of basal lev- 
els as well as the anandaergic nervous ystem in various states 
of stimulation and down regulation. The regulation and phys- 
iological relevance of anandamide as a novel neurotransmitter 
await further investigation. 
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